Lifestyle Changes and Rising Geriatric Population to Play an Instrumental Role in Expanding Global Post-Menopausal Osteoporosis Market

The global market for post-menopausal osteoporosis is driven by the measures taken by the medical fraternity to address the menstruation problems of women. Osteoporosis is characterized by low bone mass, skeletal fragility, and micro architectural disruption arising out of a systemic skeletal disorder. Prolonged menstrual cessation or menopause often results osteoporosis, thus, necessitating the need to have an effective treatment mechanism. Hence, the global market for post-menopausal osteoporosis is expected to trail along a lucrative path of growth over the coming years. A report by Transparency Market Report Research encompasses multiple factors that have aided the growth of the market in the past years. The report uses the previous market trends to foretell a trajectory of growth for the market over the coming years. The report is titled ‘Post-menopausal Osteoporosis Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024’.

Get Report Brochure @

Since menopausal osteoporosis most commonly occurs amongst women in the age group of 45 to 55 years, the rising geriatric population contributes to the demand within the market. Being habitual to smoking and consumption of alcohol aggravates post-menopausal osteoporosis. This is also an important factor that has created growth spaces within the global market for post-menopausal osteoporosis. However, competition from generics and stringent regulations with regards to the development of products within the market could hamper affluent growth.

The early adoption of treatment procedures for osteoporosis in North America has given a boost to demand within the regional market. Moreover, rising geriatric population and R&D initiatives within the region are also projected to enhance the prospects of market growth.

Some of the key players identified in the report include Oncobiologics, Inc., Enteris BioPharma, Inc., Merck & Co., Inc., and Ligand Pharmaceuticals, Inc.

View Report @

Leave a Reply